Drug Monograph

Drug/Drug Class: **D-Penamine (penicillamine) 125mg tablets / Antirheumatic Agent**
Prepared for: MO HealthNet
Prepared by: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Due to the shortage of penicillamine titratable tables in the US market, Mylan is coordinating with the FDA to temporarily import D-Penamine 125 mg tablets to address a critical drug shortage of penicillamine 250 mg titratable tablets.
Manufacturer:	Mylan New Zealand Ltd, Ellerslie AUCKLAND
Indications:	D-Penamine is indicated for severe, active rheumatoid arthritis and as a chelating agent in the treatment of Wilson's disease and lead poisoning. D-Penamine will also enhance the urinary excretion of gold and mercury and other heavy metals. Also, it is indicated In the treatment of cystinuria in cases where high-fluid regimens are not adequate, or in conjunction with them.
Costs:	$29.08 per tablet of D-Penamine. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends open access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Preferred ☐ Appropriate Indications ☒ No PA Required

Prepared By: Jennifer Anderson PharmD
Date: April 17, 2019